BioNTech Charts a New Course: Founders Exit, Buyback Launches, and Seven Cancer Readouts Loom
Published on 07/01/2026 at 05:06 | Redaktion boerse-global.de
The architects of the world’s first mRNA vaccine are stepping away from the operating table. BioNTech’s co-founders, Ugur Sahin and Özlem Türeci, will leave management at the end of 2026 to launch a new venture focused on next-generation mRNA technology. The Mainz-based company will retain a minority stake in the spin-off, with additional milestone payments and royalties tied to its progress. The move marks a clear generational shift as the group pivots fully toward oncology — and hands the reins to a broader leadership team.
Meanwhile, the company is deploying a billion-dollar shield to support its stock. A share repurchase program worth up to $1 billion kicked off in early June, funded entirely from BioNTech’s cash reserves. Chief Financial Officer Ramón Zapata described the buyback as a logical step in the firm’s capital allocation strategy. The program runs through May 2027, giving management ample time to steady the share price during a period of transition.
Investors have taken a measured view so far. BioNTech’s stock closed at €81.95 on Tuesday, edging up roughly 2% over the past week but still posting a slight year-to-date decline of less than 1%. Technically, the shares are hovering near the 50-day moving average of around €80 — a neutral zone that offers little directional conviction.
Should investors sell immediately? Or is it worth buying BioNTech?
The bigger story, however, is unfolding in the lab. BioNTech has seven late-stage clinical readouts scheduled for the second half of 2026, with total Phase 3 studies expected to reach 15 by year-end. Early data presented at the ASCO annual meeting in May and June showed encouraging anti-tumor activity from the bispecific antibody pumitamig, particularly in lung cancer when combined with chemotherapy, along with promising results for gotistobart. A regulatory filing for trastuzumab pamirtecan (T-Pam) in endometrial cancer is also on track for this year, potentially paving the way for the company’s first oncology market launch.
Financially, BioNTech is sitting on a war chest of €16.8 billion in cash as of the end of March. That firepower is critical: the company posted a net loss of €531.9 million in the first quarter as COVID-19 vaccine sales continued to slide in Europe and the U.S. The shrinking legacy business raises the stakes for the oncology pipeline. Success would validate the multi-platform strategy spanning immunomodulators, antibody-drug conjugates, and mRNA-based cancer therapies. Failure would leave BioNTech exposed to mounting operational losses and intense competition from established pharma giants.
Analysts have set a consensus price target of €106.64, not far from the 52-week high. Whether that level is reached depends entirely on the data. The next major catalysts are the remaining 2026 readouts and updates on the T-Pam filing. If the results disappoint, the fading vaccine revenue will once again dominate the narrative, putting renewed pressure on the current share price near €82.
BioNTech now faces a twin test: proving its oncology arsenal can deliver blockbuster therapies while managing a leadership transition that reshapes the company’s scientific identity. The next twelve months will be decisive.
Ad
BioNTech Stock: New Analysis - 1 July
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
